<DOC>
	<DOCNO>NCT00004386</DOCNO>
	<brief_summary>OBJECTIVES : Evaluate safety feasibility administer recombinant adenovirus contain ornithine transcarbamylase gene adult partial ornithine transcarbamylase deficiency .</brief_summary>
	<brief_title>Phase I Pilot Study Liver-Directed Gene Therapy Partial Ornithine Transcarbamylase Deficiency</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This dose escalation study estimate maximum tolerate dose recombinant adenovirus encode ornithine transcarbamylase gene . Patients receive single dose virus infuse liver fluoroscopic guidance . Groups 3 patient receive successively high dos virus ; cohort observe safety 3 week entry next group . Patients follow weekly 1 month , every 3 month stable .</detailed_description>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Confirmed partial ornithine transcarbamylase deficiency Asymptomatic , i.e. , least 1 month since hyperammonemia Prior/Concurrent Therapy Not specify Patient Characteristics No pregnant nursing woman Negative pregnancy test require fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>urea cycle disorder</keyword>
</DOC>